Open AccessPhase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors
Author(s) -
Trần Vân Khánh,
Geraldine Helen O'Sullivan Coyne,
John L. Hays,
Jeffrey G. Supko,
Stephen V. Liu,
Kristin Beebe,
Len Neckers,
Jane B. Trepel,
Min-Jung Lee,
Tomoko Smyth,
Courtney Gan,
Jennifer Hedglin,
Alona Muzikansky,
Susana M. Campos,
John F. Lyons,
Percy Ivy,
James H. Doroshow,
Alice Chen,
Geoffrey I. Shapiro
Publication year - 2020
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-020-04176-z
Subject(s) - medicine , nausea , adverse effect , vomiting , pharmacodynamics , pharmacokinetics , mucositis , pharmacology , hsp90 inhibitor , oncology , gastroenterology , carboplatin , cancer , toxicity , heat shock protein , chemotherapy , cisplatin , hsp90 , biochemistry , chemistry , gene
We conducted a phase 1 trial of the HSP90 inhibitor onalespib in combination with the CDK inhibitor AT7519, in patients with advanced solid tumors to determine the safety profile and maximally tolerated dose, pharmacokinetics, preliminary antitumor activity, and to assess the pharmacodynamic (PD) effects on HSP70 expression in patient-derived PBMCs and plasma.